Literature DB >> 12970078

Effects of the CGRP receptor antagonist BIBN4096BS on capsaicin-induced carotid haemodynamic changes in anaesthetised pigs.

Kapil Kapoor1, Udayasankar Arulmani, Jan P C Heiligers, Ingrid M Garrelds, Edwin W Willems, Henri Doods, Carlos M Villalón, Pramod R Saxena.   

Abstract

1. Calcitonin gene-related peptide (CGRP), a potent vasodilator released from capsaicin-sensitive trigeminal sensory nerves, seems to be involved in the pathogenesis of migraine. Hence, CGRP receptor antagonists may serve as a novel treatment for migraine. This study was therefore designed to investigate the effects of BIBN4096BS (100, 300 and 1000 microg kg-1, i.v.), a potent and selective CGRP receptor antagonist, on capsaicin-induced carotid haemodynamic changes in anaesthetised pigs. Both vagosympathetic trunks were cut and phenylephrine was infused into the carotid artery (i.c.) to support carotid vascular tone. 2. Infusions of capsaicin (0.3, 1, 3 and 10 microg kg-1 min-1, i.c.) did not alter the heart rate, but dose-dependently increased the mean arterial blood pressure. This moderate hypertensive effect was not modified by BIBN4096BS. 3. Capsaicin infusion (10 microg kg-1 min-1, i.c.) increased total carotid, arteriovenous anastomotic and tissue blood flows and conductances as well as carotid pulsations, but decreased the difference between arterial and jugular venous oxygen saturations. These responses to capsaicin were dose-dependently blocked by BIBN4096BS. 4. Capsaicin infusion (10 microg kg-1 min-1, i.c.) more than doubled the jugular venous plasma concentration of CGRP. This effect was not blocked, but rather increased, by BIBN4096BS. 5. The above results show that BIBN4096BS behaves as a potent antagonist of capsaicin-induced carotid haemodynamic changes that are mediated via the release of CGRP. Therefore, this compound may prove effective in the treatment of migraine.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12970078      PMCID: PMC1574043          DOI: 10.1038/sj.bjp.0705451

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  53 in total

1.  Pharmacological evidence for CGRP uptake into perivascular capsaicin sensitive nerve terminals.

Authors:  A Sams-Nielsen; C Orskov; I Jansen-Olesen
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

Review 2.  Neuronal messengers in the human cerebral circulation.

Authors:  S Gulbenkian; R Uddman; L Edvinsson
Journal:  Peptides       Date:  2001-06       Impact factor: 3.750

3.  The peptidergic innervation of human coronary and cerebral vessels.

Authors:  S Gulbenkian; C P Barroso; M Cunha e Sá; L Edvinsson
Journal:  Ital J Anat Embryol       Date:  1995

Review 4.  Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy.

Authors:  P Tfelt-Hansen; P De Vries; P R Saxena
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

Review 5.  Neurogenic inflammation in the context of migraine.

Authors:  D J Williamson; R J Hargreaves
Journal:  Microsc Res Tech       Date:  2001-05-01       Impact factor: 2.769

6.  Release of calcitonin gene-related peptide (CGRP) from guinea pig dura mater in vitro is inhibited by sumatriptan but unaffected by nitric oxide.

Authors:  C T Eltorp; I Jansen-Olesen; A J Hansen
Journal:  Cephalalgia       Date:  2000-11       Impact factor: 6.292

7.  Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist.

Authors:  H Doods; G Hallermayer; D Wu; M Entzeroth; K Rudolf; W Engel; W Eberlein
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

8.  Characterisation of calcitonin gene-related peptide receptors in rat atrium and vas deferens: evidence for a [Cys(Et)(2, 7)]hCGRP-preferring receptor.

Authors:  D Wu; W Eberlein; K Rudolf; W Engel; G Hallermayer; H Doods
Journal:  Eur J Pharmacol       Date:  2000-07-21       Impact factor: 4.432

Review 9.  The molecular pharmacology of CGRP and related peptide receptor subtypes.

Authors:  C Juaneda; Y Dumont; R Quirion
Journal:  Trends Pharmacol Sci       Date:  2000-11       Impact factor: 14.819

10.  Lack of effect of sumatriptan and UK-14,304 on capsaicin-induced relaxation of guinea-pig isolated basilar artery.

Authors:  C T O'Shaughnessy; G J Waldron; H E Connor
Journal:  Br J Pharmacol       Date:  1993-01       Impact factor: 8.739

View more
  8 in total

Review 1.  Chemical mediators of migraine: preclinical and clinical observations.

Authors:  Saurabh Gupta; Stephanie J Nahas; B Lee Peterlin
Journal:  Headache       Date:  2011-06       Impact factor: 5.887

2.  Donitriptan, but not sumatriptan, inhibits capsaicin-induced canine external carotid vasodilatation via 5-HT1B rather than 5-HT1D receptors.

Authors:  E Muñoz-Islas; S Gupta; L R Jiménez-Mena; J Lozano-Cuenca; A Sánchez-López; D Centurión; S Mehrotra; A MaassenVanDenBrink; C M Villalón
Journal:  Br J Pharmacol       Date:  2006-07-31       Impact factor: 8.739

3.  The nonpeptide calcitonin gene-related peptide receptor antagonist BIBN4096BS lowers the activity of neurons with meningeal input in the rat spinal trigeminal nucleus.

Authors:  Michael Jochen Marco Fischer; Stanislav Koulchitsky; Karl Messlinger
Journal:  J Neurosci       Date:  2005-06-22       Impact factor: 6.167

Review 4.  Cardiovascular pharmacology of cannabinoids.

Authors:  P Pacher; S Bátkai; G Kunos
Journal:  Handb Exp Pharmacol       Date:  2005

5.  Effects of current and prospective antimigraine drugs on the porcine isolated meningeal artery.

Authors:  Suneet Mehrotra; Saurabh Gupta; Ingrid M Garrelds; Carlos M Villalón; Pramod R Saxena; Ad J J C Bogers; Antoinette Maassenvandenbrink
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-11-14       Impact factor: 3.000

6.  CGRP receptor antagonists: A new frontier of anti-migraine medications.

Authors:  Blanca Marquez de Prado; Andrew F Russo
Journal:  Drug Discov Today Ther Strateg       Date:  2006

Review 7.  Current and prospective pharmacological targets in relation to antimigraine action.

Authors:  Suneet Mehrotra; Saurabh Gupta; Kayi Y Chan; Carlos M Villalón; David Centurión; Pramod R Saxena; Antoinette MaassenVanDenBrink
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-15       Impact factor: 3.000

8.  Haemodynamic profile and responsiveness to anandamide of TRPV1 receptor knock-out mice.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  J Physiol       Date:  2004-04-30       Impact factor: 5.182

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.